Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) is a developer of exoskeleton and rehabilitation technologies for medical and industrial applications, and its news flow reflects this focus. Company press releases highlight product and technology developments, capital markets activity, strategic partnerships, and financial performance. Ekso Bionics regularly describes itself as an industry leader in exoskeleton technology that supports or enhances human strength, endurance, and mobility, with an emphasis on improving health and quality of life.
News updates for EKSO often cover clinical and rehabilitation initiatives, such as the launch of eksoUniversity, a virtual platform offering continuing education courses for physical therapists and physical therapy assistants who work with patients with neurological conditions. Other announcements detail agreements like Ekso Bionics’ role as the exclusive authorized U.S. sales agent and distributor for MediTouch’s BalanceTutor rehabilitation system, which uses a patented 4D perturbation treadmill and multiple sensors to help patients with impaired balance respond to unexpected disturbances while walking.
Investors and observers can also find coverage of Ekso Bionics’ technology roadmap, including its acceptance into the NVIDIA Connect program and related efforts to build a proprietary foundation model for human motion and integrate AI-enabled capabilities into its Enterprise Health and Personal Health exoskeleton devices. The company has reported proof-of-concept for an AI voice agent, Ekso Voice Agent, designed for intelligent control of its legacy EksoNR device.
In addition, EKSO news includes quarterly financial results, reverse stock split announcements, registered direct offerings of common stock, and secured loan agreements. Together, these updates provide insight into the company’s operating trends, capital structure decisions, and strategic priorities. This news page aggregates such disclosures so readers can follow developments in Ekso Bionics’ exoskeleton, rehabilitation, and AI initiatives over time.
Ekso Bionics (NASDAQ: EKSO) has been accepted into the prestigious NVIDIA Connect program, marking a significant step in the company's AI development strategy. The exoskeleton technology leader plans to leverage NVIDIA's resources to develop the world's first foundation model for human motion in physical rehabilitation.
Through this selective program, Ekso Bionics will gain access to specialized training, priority engineering support, and exclusive NVIDIA GPU platforms and development kits. The company aims to integrate new AI capabilities across its Enterprise Health and Personal Health device portfolio. CEO Scott Davis emphasized that while their exoskeleton technology is already advanced, this collaboration represents just the beginning of their AI journey in rehabilitation technology.
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its Q1 2025 financial results announcement for May 5, 2025, after market close.
The company will host a conference call on the same day at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss:
- First quarter 2025 financial performance
- Recent business developments
- Company updates
Interested participants can join the conference call by dialing:
The presentation will be broadcast live and archived on the company's investor relations website at www.eksobionics.com under the "Presentations & Events" section.
Ekso Bionics (Nasdaq: EKSO) has announced a non-exclusive distribution agreement with Bionic Prosthetics & Orthotics Group (Bionic P&O) for the Ekso Indego® Personal device, marking the company's first entry into the orthotics & prosthetics industry.
The Ekso Indego Personal is a wearable powered exoskeleton for individuals with spinal cord injuries (SCIs), featuring:
- Modular quick connect design for independent use
- Lightest commercial exoskeleton available
- Advanced gait mode enabling faster walking speeds
- Enhanced independence for users
This strategic alliance aims to leverage Bionic P&O's expertise in market dynamics, reimbursement landscape, and patient needs to effectively distribute the innovative device within the O&P community.
Ekso Bionics (NASDAQ: EKSO) reported its Q4 and full-year 2024 financial results, achieving record Q4 revenue of $5.1 million, up 5% year-over-year. Q4 gross margin improved by 400 basis points to 53%. The company recently named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor in the U.S.
For full-year 2024, revenue was $17.9 million, down 2% from 2023. Gross profit reached $9.5 million with a 53% margin. Net loss improved by 25% to $11.3 million ($0.56 per share) compared to $15.2 million in 2023. Operating expenses decreased across all categories, with cash usage improving to $9.8 million from $12.1 million in 2023. The company ended 2024 with $6.5 million in cash and restricted cash.
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss financial results and recent business developments. Investors can participate via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be available through a live broadcast and archive on the company's investor relations website.
Ekso Bionics Holdings (NASDAQ: EKSO) has named National Seating & Mobility (NSM) as the exclusive distributor of Ekso Indego® Personal device within the Complex Rehabilitation Technology (CRT) industry in the United States. The Ekso Indego Personal is a powered exoskeleton that enables individuals with spinal cord injuries to stand and walk independently.
The device features a unique modular quick connect design allowing users to operate it without assistance, and is the lightest commercial exoskeleton available. Users have demonstrated faster walking speeds with its advanced gait mode, enhancing their community independence.
NSM, a leading provider of CRT and mobility solutions, will leverage its expertise and insurance partnerships to expand access to the technology. The partnership aligns with Ekso Bionics' growth strategy and aims to broaden the availability of innovative mobility solutions.
Ekso Bionics (NASDAQ: EKSO) has announced preliminary Q4 2024 financial results, expecting record revenues between $5.0-$5.1 million, up from $4.8 million in Q4 2023. The company highlighted progress with initial CMS reimbursement for Ekso Indego Personal, expanding Medicare patient access.
Cash position as of December 31, 2024, stood at $6.5 million, down from $8.6 million year-over-year. Net cash used in operations for Q4 2024 was approximately $1.5 million, slightly improved from $1.6 million in Q4 2023. The company notes these are preliminary unaudited results subject to potential adjustments during the final review process.
Ekso Bionics announced that Katherine Strausser, Principal Controls Engineer, will participate in an 'AI for Good' webinar titled 'AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility' on Tuesday, November 19 at 10:00 a.m. ET. The session will explore latest exoskeleton technologies and challenges in medical rehabilitation. Katherine, who holds a Ph.D. in Mechanical Engineering and is one of the original inventors of the EksoNR device, specializes in controls systems for robotics and human-exoskeleton interaction.
Ekso Bionics Holdings (Nasdaq: EKSO), a leader in medical and industrial exoskeleton technology, has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York. CEO Scott Davis and CFO Jerome Wong will conduct one-on-one meetings with institutional investors during the event. Interested investors should contact their Craig-Hallum representative to schedule meetings.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
